West Pharma Shares Surge 15% on Raised 2026 Profit Forecast, Q1 Beat
Summary
West Pharmaceutical Services significantly raised its full-year 2026 adjusted profit per share forecast to $8.40-$8.75 (from $7.85-$8.20) and its 2026 sales outlook to $3.29B-$3.35B (from $3.215B-$3.275B). The company also reported a strong first-quarter beat, with adjusted EPS of $2.13 (vs. $1.68 estimate) and revenue of $844.9 million (vs. $780 million estimate). This positive update, driven by robust demand for medical equipment and components for injectable drugs, including those from Eli Lilly, has sent shares up over 15%. The news alleviates recent investor concerns regarding the potential impact of oral obesity drugs on demand for injectable therapies. Traders should monitor the sustainability of demand for injectable products and the company's ability to manage input costs.
At the time of this announcement, WST was trading at $313.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $22.6B. The 52-week trading range was $199.89 to $322.34. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.